Article Sidebar

PDF
Date Published: 09/10/2022
Abstract Views: 238
Views PDF: 489
DOI: https://doi.org/10.51298/vmj.v518i2.3424
Issue
Vol. 518 No. 2 (2022)
Section
Các bài báo
How to Cite
Thị Kim Hương, N. ., Thị Nhật Lệ, N. ., & Hữu Doanh, L. . (2022). EFFECTIVENESS OF LICHEN SCLEROSUS WITH ORAL AZITHROMYCIN. Vietnam Medical Journal, 518(2). https://doi.org/10.51298/vmj.v518i2.3424

EFFECTIVENESS OF LICHEN SCLEROSUS WITH ORAL AZITHROMYCIN

Nguyễn Thị Kim Hương1,, Nguyễn Thị Nhật Lệ2, Lê Hữu Doanh3,4
1 Friendship Hospital
2 Vietnam - Cuba Hospital
3 Hanoi Medical University
4 National Hospital of Dermatology and Venereology

Main Article Content

Abstract

A uncontrolled, before-and-after clinical trial to evaluate the efficacy and adverse effects of oral azithromycin in the treatment of lichen sclerosus. The study was conducted on 30 patients at the National Hospital of Dermatology. The study results showed that, after 8 weeks, the proportion of patients who responded to treatment (66.67%), good response accounted for (26.67%), only 2 patients did not respond, accounting for a low rate (6.66%). Adverse side effects: 10% had nausea, diarrhea; 16.67% had abdominal pain in the first 1-2 days, no patient refused treatment.

Article Details

Keywords

lichen sclerosus, chronic, azithromycin

References

1. Patel DG, Kihiczak G, Schwartz RA, Janniger CK, Lambert WC (2000). Pityriasis lichenoides. Cutis; 65: 17-23.
2. Piamphongsant T (1974). Tetracycline for the treatment of pityriasis lichenoides. Br J Dermatol. Sep. 91(3):319-22.
3. LeVine MJ (1983). Phototherapy of pityriasis lichenoides. Arch Dermatol. May. 119(5):378-80.
4. R. B Skinner and A. L. Levy (2008). Rapid resolution of pityriasis lichenoides et varioliformis acuta with azithromycin, Journal of the American Academy of Dermatology, vol. 58, no.3, pp. 524-525.
5. Aydogan K, Saricaoglu H, Turan H (2008). Narrowband UVB (311 nm, TL01) phototherapy for pityriasis lichenoides.Photodermatol
6. Hapa A, Ersoys-Evans S. Karaduman A (2012). Childhood pityriasis lichenoides and oral erythromycin. Pediatr Dermatol; 29: 719-724.
7. U.S Food and Drug Administration (2014). FDA Drug safety communication: Azithromycin (zithromax or Zmax) and the risk of potentially fatal heart rhythms. Accessed on August 27, 2014.